Improved therapy of myotonia with the lidocaine derivative tocainide

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/BF00313157PMID 6154787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful treatment ofparamyotonia congenita (Eulenburg): musclestiffness andweakness prevented bytocainide

  1980cited by this paper
• Effects of tocainide on normal and myotonic mammalian skeletal muscle.

  1979cited by this paper
• Clinical Electrophysiologic Effects of Tocainide

  1978cited by this paper
• Long-Term Tocainide Therapy for Ventricular Arrhythmias

  1978cited by this paper
• Clinical electrophysiologic effects of tocainide.

  1978cited by this paper
• Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin

  1975cited by this paper
• Side effects of antiarrhythmic drugs

  1971cited by this paper
• Therapy of myotonia;

  1967cited by this paper

• Drug treatment for myotonia.

  2025influential citation
• Voltage-gated sodium channels in excitable cells as drug targets

  2025cites this paper
• Treatment and Management of Disorders of Neuromuscular Hyperexcitability and Periodic Paralysis

  2022cites this paper
• Flecainide-Responsive Myotonia Permanens With SNEL Onset: A New Case and Literature Review

  2016cites this paper
• Channelopathies of skeletal muscle excitability.

  2015cites this paper
• Disorders of Skeletal Muscle Membrane Excitability: Myotonia Congenita, Paramyotonia Congenita, Periodic Paralysis, and Related Syndromes

  2014cites this paper
• Repurposing of sodium channel antagonists as potential new anti-myotonic drugs.

  2014cites this paper
• The diagnosis and treatment of myotonic disorders

  2013cites this paper
• Molecular pathophysiology of voltage-gated ion channels . Chapter 128 in : Reviews of Physiology Biochemistry and Pharmacology 1996

  2013cites this paper
• Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

  2012cites this paper
• Skeletal Muscle Na+ Channel Disorders

  2011cites this paper
• 17 – Treatment and Management of Disorders of Neuromuscular Hyperexcitability

  2011cites this paper
• Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1

  2010cites this paper
• The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

  2010cites this paper
• Sodium channelopathies of skeletal muscle result from gain or loss of function

  2010cites this paper
• Myotonia Congenita and Myotonic Dystrophy: Surveillance and Management

  2010cites this paper
• Novel CLCN1 Mutations and Clinical Features of Korean Patients with Myotonia Congenita

  2009cites this paper
• Myotonia congenita.

  2008cites this paper
• CASE 97 – A Young Man with Large and Stiff Muscles

  2008cites this paper
• [Eulenburg's paramyotonia congenita].

  2007cites this paper
• Paramyotonie congénitale d’Eulenburg

  2007cites this paper
• Drug treatment for myotonia.

  2006cites this paper
• Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.

  2006cites this paper
• Twee families met stijve spieren:: de niet-dystrofische myotonieën

  2006cites this paper
• Treatment in myotonia and periodic paralysis.

  2004cites this paper
• Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of curschmann-steinert

  2004cites this paper
• Mexiletine block of disease‐associated mutations in S6 segments of the human skeletal muscle Na+ channel

  2001cites this paper
• Does abnormal neuronal excitability exist in myotonic dystrophy)?¶I. Effects of the antiarrhythmic drug hydroquinidine on slow saccadic eye movements

  2000cites this paper
• Quantitative myotonia assessment: an experimental protocol

  2000cites this paper
• Therapy in myotonic disorders and in muscle channelopathies

  2000cites this paper
• Voltage-gated ion channels and hereditary disease.

  1999cites this paper
• Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.

  1997cites this paper
• Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide

  1997cites this paper
• Molecular pathophysiology of voltage-gated ion channels.

  1996cites this paper
• Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers

  1995cites this paper
• The skeletal muscle sodium and chloride channel diseases.

  1995cites this paper
• Paramyotonia congenita: Abnormal short exercise test, and improvement after mexiletine therapy

  1994cites this paper
• [Myotonia congenital (Thomsen) and recessive generalized myotonia (Becker)].

  1993cites this paper
• Treatment of myotonia with antiarrhythmic drugs

  1992cites this paper
• Neuromyotonia in hereditary motor neuropathy.

  1991cites this paper
• Tocainide therapy in muscle cramps and spasms due to neuromuscular disease

  1991cites this paper
• Paramyotonia Congenita

  1991cites this paper
• The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation

  1991cites this paper
• Inactivation of human sodium channels and the effect of tocainide

  1990cites this paper
• Schwartz–Jampel syndrome: II. Na+ channel defect causes myotonia

  1990cites this paper
• Procainamide for dyspnea in myotonic dystrophy.

  1989cites this paper
• Transient weakness and altered membrane characteristic in recessive generalized myotonia (Becker)

  1988cites this paper
• The myotonic mouse mutant ADR: Electrophysiology of the muscle fiber

  1988cites this paper
• Congenital and acquired neuromuscular disease of young dogs and cats.

  1987cites this paper
• Action of tocainide and mexiletine on the excitation threshold of myelinated nerves.

  1987cites this paper
• Treatment of myotonia.

  1987cites this paper
• AAEE minimonograph #27: Differential diagnosis of myotonic syndromes

  1987cites this paper
• Successful treatment with tocainide of recessive generalized congenital myotonia

  1986cites this paper
• Effect of tocainide on the concentrations of norepinephrine dopamine, serotonin and histamine in rat brain and its binding affinity to neuroceptors.

  1985cites this paper
• Membrane changes in cells from myotonia patients.

  1985cites this paper
• Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia.

  1985cites this paper
• Different effectiveness of tocainide and hydrochlorothiazide in paramyotonia congenita with hyperkalemic episodic paralysis

  1983cites this paper
• [Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine].

  1983cites this paper
• Depressant effects of drugs used in myotonia therapy.

  1982cites this paper
• Ouabain and tetrodotoxin block the myotonia of skeletal muscle induced with 20,25-diazacholesterol.

  1982cites this paper
• Hereditary myotonia in the chow chow.

  1981cites this paper
• dystrophy type 1 Mexiletine is an effective antimyotonia treatment in myotonic

  year unknowncites this paper